Kudos to the World Health Organisation for publishing age-disaggregated data on its vaccination coverage portal.
Estimating excess mortality in the first wave of Peru’s COVID-19 pandemic: more than just an academic exercise?
Lancet Americas has just published a paper in which we develop a new method for estimating excess numbers of deaths during the COVID-19 pandemic and applies this method to Peru
An emergency strategy for managing COVID-19 in long-term care facilities in low and middle-income countries: the CIAT Framework (Version 3*).
There is a broad misperception that there are very few long-term care facilities (LTCFs) in low and middle-income countries (LMICs). In fact, there are large and rapidly growing networks of residential care services for older people in Latin America, many parts of Asia, South Africa and other middle-income settings (Camarano et al, 2010; Cheung Wong and Leung, 2012; Lloyd-Sherlock, 2019).
The direct and indirect effects of the COVID-19 pandemic on older people in low and middle-income countries: one year on
In March 2020, the BMJ published a comment on the potential effects that the COVID-19 pandemic might have on older adults in low and middle-income countries (LMICs) . This predicted that older people in LMICs would account for a large share of COVID-19 mortality, since these countries contain around 70 per cent of the global population aged 60 or more and there is less access to effective health interventions than in high-income countries.
The CIAT emergency strategy framework for managing covid-19 in long-term care facilities: the case of Brazil
Over the past year, members of the Global Platform have worked together to produce a set of emergency guidance for managing the COVID-19 pandemic in long-term care facilities. This guidance pays particular attention to the contexts of low and middle-income countries.
A call for WHO and Global Health Agencies to address the exclusion of older people from trials and research in vaccines and health interventions.
Why were older people either absent or only marginally represented in trials of many COVID-19 vaccines? What lessons can we take from this moving forward?